Valneva SE (VALN) Other Non-Current Liabilities (2020 - 2026)

Valneva SE (VALN) posted quarterly Other Non-Current Liabilities of $14.0 million for Q1 2026, up 115.78% year-on-year from $6.5 million in Q1 2025, and up 5.79% on a QoQ basis from $13.3 million in Q4 2025.

Valneva SE (VALN) Other Non-Current Liabilities (2020 - 2026) Analysis & Trends

Valneva SE (VALN) has reported Other Non-Current Liabilities for 7 consecutive years, with $14.0 million the latest figure, recorded in Q1 2026.

  • Quarterly Other Non-Current Liabilities rose 115.78% year-over-year to $14.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.0 million (up 115.78% YoY) and the FY2025 annual result came in at $13.3 million, up 1953.58% from the prior year.
  • Other Non-Current Liabilities grew to $14.0 million in Q1 2026 per VALN's latest filing, from $13.3 million in the prior quarter.
  • Over the last five years, Other Non-Current Liabilities for VALN reached as high as $64.7 million in Q2 2022 and fell as low as $621323.0 in Q4 2024.
  • A 5-year average of $15.7 million and a median of $10.9 million in 2024 frame the typical range for Other Non-Current Liabilities.
  • Annual changes were most pronounced in 2022 — Other Non-Current Liabilities plunged 83.4% — and 2025, when it soared 2035.35%.
  • Year by year, Other Non-Current Liabilities stood at $1.6 million in 2022, then decreased by 22.12% to $1.2 million in 2023, then plunged by 49.16% to $621323.0 in 2024, then surged by 2035.35% to $13.3 million in 2025, then climbed by 5.79% to $14.0 million in 2026.
  • According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $14.0 million, $13.3 million, and $12.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn
4 NuCana 279.75 Bn 279.75 Bn -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn
7 Belite Bio 62.51 Bn 62.51 Bn -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn -
10 Valneva SE 803.90 Mn 680.66 Mn 5.38 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 14.04 Mn
Dec 31, 2025 13.27 Mn
Sep 30, 2025 12.03 Mn
Jun 30, 2025 6.66 Mn
Mar 31, 2025 6.50 Mn
Dec 31, 2024 621,323.03
Sep 30, 2024 8.30 Mn
Jun 30, 2024 7.92 Mn
Mar 31, 2024 10.87 Mn
Dec 31, 2023 1.22 Mn
Sep 30, 2023 10.82 Mn
Jun 30, 2023 14.40 Mn
Mar 31, 2023 27.35 Mn
Dec 31, 2022 1.57 Mn
Sep 30, 2022 31.51 Mn
Jun 30, 2022 64.73 Mn
Mar 31, 2022 34.77 Mn
Dec 31, 2021 9.45 Mn
Dec 31, 2020 3.31 Mn